Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.

Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, Krevvata M, Stanziola J, Loi M, Van Brummelen EMJ, Lopez-Masi L, Rowe M, Carson RL, Zweegman S

Open source

DOI: 10.1200/jco-26-00401
Published: 2026 Sep 25
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00401,
  title = {Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.},
  author = {Usmani SZ and Facon T and Hungria V and Bahlis NJ and Venner CP and Braunstein M and Pour L and Marti JM and Basu S and Cohen YC and Matsumoto M and Suzuki K and Hulin C and Grosicki S and Legiec W and Beksac M and Maiolino A and Takamatsu H and Perrot A and Turgut M and Liu W and Wang J and Krevvata M and Stanziola J and Loi M and Van Brummelen EMJ and Lopez-Masi L and Rowe M and Carson RL and Zweegman S},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-26-00401},
  url = {https://doi.org/10.1200/jco-26-00401}
}

RIS

TY  - JOUR
TI  - Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
AU  - Usmani SZ
AU  - Facon T
AU  - Hungria V
AU  - Bahlis NJ
AU  - Venner CP
AU  - Braunstein M
AU  - Pour L
AU  - Marti JM
AU  - Basu S
AU  - Cohen YC
AU  - Matsumoto M
AU  - Suzuki K
AU  - Hulin C
AU  - Grosicki S
AU  - Legiec W
AU  - Beksac M
AU  - Maiolino A
AU  - Takamatsu H
AU  - Perrot A
AU  - Turgut M
AU  - Liu W
AU  - Wang J
AU  - Krevvata M
AU  - Stanziola J
AU  - Loi M
AU  - Van Brummelen EMJ
AU  - Lopez-Masi L
AU  - Rowe M
AU  - Carson RL
AU  - Zweegman S
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-26-00401
UR  - https://doi.org/10.1200/jco-26-00401
ER  -

APA

SZ, U., T, F., V, H., NJ, B., CP, V., M, B., L, P., JM, M., S, B., YC, C., M, M., K, S., C, H., S, G., W, L., M, B., A, M., H, T., A, P., M, T., W, L., J, W., M, K., J, S., M, L., EMJ, V. B., L, L., M, R., RL, C., & S, Z. (2026). Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-26-00401

Source records

pubmed · retrieved 2026-09-25T23:44:07.313Z